6
项与 Allogeneic Mesenchymal Stem Cells(Jiuzhitang Maker Cell Technology) 相关的临床试验A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Multicenter, Blind, Randomized, Placebo Controlled Single Injection of It-hMSC in Patients With Ischemic Stroke
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo controlled trial
评估向缺血性脑卒中患者单次注射it-hMSC的多中心、盲法、随机、安慰剂对照的安全性、耐受性和初步疗效的I/IIa期研究
主要目的:评估对缺血性脑卒中患者静脉注射it-hMSC的安全性和耐受性。次要目的:评估it-hMSC的治疗具有神经和运动功能障碍的缺血性脑卒中患者的临床疗效。
/ Unknown status临床1/2期IIT A Multicenter, Blind, Randomized, Placebo-controlled Phase I / IIA Study to Evaluate the Safety, Tolerability, and Initial Efficacy of a Single Injection of Ischemia Tolerant Human Allogeneic Bone Marrow Mesenchymal Stem Cells in Patients With Ischemic Stroke
Stroke is the main cause of adult health damage. 20% of stroke survivors need institutional care after 3 months, and up to 30% of them have severe or permanent disability. Stem cells are a kind of pluripotent cells with the ability of self replication. The self-renewal and differentiation characteristics of mesenchymal stem cells, as well as cytokine secretion effect and immune characteristics, provide the possibility for mesenchymal stem cells to treat ischemic stroke. After the infusion of mesenchymal stem cells, the secretion of soluble media including growth factors and cytokines may be the main mechanism of mesenchymal stem cells.
100 项与 Allogeneic Mesenchymal Stem Cells(Jiuzhitang Maker Cell Technology) 相关的临床结果
100 项与 Allogeneic Mesenchymal Stem Cells(Jiuzhitang Maker Cell Technology) 相关的转化医学
100 项与 Allogeneic Mesenchymal Stem Cells(Jiuzhitang Maker Cell Technology) 相关的专利(医药)
100 项与 Allogeneic Mesenchymal Stem Cells(Jiuzhitang Maker Cell Technology) 相关的药物交易